Understanding the Market | SINOMAB BIO-B rose over 7% in the afternoon as the bridging study for the subcutaneous injection formulation of SM17 in China completed dosing of the first cohort of healthy subjects

SINOMAB BIO-B's stock price rose over 7% in the afternoon, with an increase of 6.33% as of the time of publication, trading at HKD 1.68, with a transaction volume of HKD 11.7838 million. The company announced that the bridging study for the subcutaneous injection formulation of SM17 has successfully completed the administration to the first cohort of healthy subjects, with all subjects tolerating well and no adverse events reported. The study aims to investigate the safety, tolerability, and pharmacokinetic characteristics of SM17, with recruitment expected to be completed by November 2025 and follow-up completed by March 2026. SM17 is the world's first humanized IgG4-κ monoclonal antibody, with the potential to treat skin inflammation